CDRIC LOIRET-BERNAL, M.D., is president and chief executive officer as
well as a member of the board of directors of NanoInk.Inc. He joined the
company in October 2003. Dr. Loiret-Bernal is the former chief executive
officer and co-founder of GeneProt Inc., an industrial-scale proteomics
company for which he raised more than $150 million from institutional
investors and corporate partners such as Novartis, Compaq Bruker. Dr.
Loiret-Bernal joins NanoInk from CDP Capital Technology Ventures, the
largest Canadian institutional investor. At CDP, he was venture advisor
for life sciences investments in the U.S. Prior to GeneProt, he was a
partner and senior investment analyst at Brinson Partners (now part of
UBS Global Asset Management), an asset management division with
healthcare holdings in excess of $3 billion. He also held many other
senior positions in corporate strategic planning for Abbott
Laboratories, in marketing at Haemonetics and Porgs-Synthlabo. Dr.
Loiret-Bernal holds a doctor of medicine degree, summa cum laude, from
the University of Bordeaux and has an MBA degree from the J.L. Kellogg
Graduate School of Management, Northwestern University.
